1. Home
  2. RXO vs ERAS Comparison

RXO vs ERAS Comparison

Compare RXO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

HOLD

Current Price

$23.45

Market Cap

4.0B

Sector

N/A

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.29

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXO
ERAS
Founded
2022
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.0B
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
RXO
ERAS
Price
$23.45
$18.29
Analyst Decision
Hold
Strong Buy
Analyst Count
13
12
Target Price
$16.33
$14.25
AVG Volume (30 Days)
2.1M
3.7M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
72.81
36.23
EPS
N/A
N/A
Revenue
$5,742,000,000.00
N/A
Revenue This Year
$0.49
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.20
N/A
52 Week Low
$10.43
$1.33
52 Week High
$29.90
$24.28

Technical Indicators

Market Signals
Indicator
RXO
ERAS
Relative Strength Index (RSI) 49.12 50.90
Support Level $11.40 $17.36
Resistance Level $29.46 $19.96
Average True Range (ATR) 1.44 1.02
MACD 0.20 -0.16
Stochastic Oscillator 90.56 53.27

Price Performance

Historical Comparison
RXO
ERAS

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: